Drug General Information (ID: DDIGOSJ1P2)
Drug Name			Eptifibatide		Drug Info		Anagrelide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antithrombotic Agents
Structure

Mechanism of Eptifibatide-Anagrelide Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Eptifibatide				Anagrelide
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Eptifibatide and Anagrelide

Recommended Action
Management		Extraordinary precautions are recommended if these drugs must be used together, including monitoring platelet counts and hemoglobin concentrations. In addition, invasive procedures, such as urinary catheterization, nasogastric or nasotracheal intubation, and even venous punctures should be avoided or minimized. Non-compressible venous access sites, such as jugular or subclavian sites, should be avoided.

References
1	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
2	Product Information. ReoPro (abciximab). Lilly, Eli and Company, Indianapolis, IN.